The test uses a fairly short nasal swab to gather a sample. The sample is put into a digital analyzer linked to a mobile phone app. In December, the company told NPR the test would be available for about $30.
The Food and Drug Administration gave emergency situation permission to Ellumes quick test in December, after it showed 96% accuracy in a U.S. medical research study. Those trials consisted of both grownups and kids of ages 2 years and older.
The test uses a fairly brief nasal swab to gather a sample. The sample is put into a digital analyzer linked to a smartphone app. In December, the business informed NPR the test would be readily available for about $30.
Ellume states it will develop its very first U.S.-based factory to make the tests, increase towards producing 19 million sets each month later this year.
Ellume Limited, an Australian business, makes a 15-minute at-home test for the coronavirus which triggers COVID-19.
The company got $30 million in 2015 from the U.S. National Institutes of Health Rapid Acceleration of Diagnostics initiative to support clinical testing and manufacture of the test.
As part of the new agreement, Ellume has dedicated to providing 8.5 million tests to the federal government, said Andy Slavitt, senior advisor to the White House COVID-19 Response Team.
The Biden administration has actually made a $231.8 million handle an Australian business to increase availability of the first at-home rapid test for the coronavirus which triggers COVID-19 that is available without a prescription. The test, made by Ellume, can send out results to a smart device within 15 minutes of getting a sample.
Ellume Limited, an Australian company, manufactures a 15-minute at-home test for the coronavirus which causes COVID-19.